Nivestym is used to manage neutropenia, a condition characterized by a low count of neutrophils, which are a type of white blood cell essential for fighting infection. The drug helps to stimulate the production of these infection-fighting cells.

Quick Facts

• Condition Treated: Neutropenia.
• Primary Benefit: Reduction of the risk and incidence of fever associated with low neutrophil counts (febrile neutropenia).
• Key Uses:
  • Decrease the incidence of infection in patients with non-myeloid malignancies receiving chemotherapy that can suppress bone marrow function.
  • Reduce the duration of neutropenia in patients with acute myeloid leukemia (AML) receiving chemotherapy.
  • Manage persistent neutropenia in patients with severe chronic neutropenia, which includes congenital, cyclic, or idiopathic types, to reduce the duration of related clinical sequelae like fever and infections.
  • Mobilize blood cells for collection in patients undergoing autologous peripheral blood progenitor cell (PBPC) collection and therapy.

Nivestym is indicated to reduce the duration of neutropenia and its associated clinical consequences, such as infection, in various patient populations. These applications represent the authorized clinical uses for the management of these conditions.

Regulatory References

1. EMA therapeutic overview

Nivestym's population eligibility is strictly defined by regulatory authorities, outlining groups who must use the medicine, who must not, and who requires restricted use. This information is based exclusively on official labeling.

Populations Excluded or Contraindicated

Classification	Population Restriction
Absolute Contraindication	Patients with a history of serious allergic reactions (hypersensitivity) to human G-CSF products (filgrastim or pegfilgrastim).
Explicitly Not Indicated	Patients diagnosed with Chronic Myeloid Leukemia (CML) or Myelodysplastic Syndromes (MDS).

Restricted or Conditional Use

Use of Nivestym requires special consideration in specific patient groups:

• Sickle Cell Disorder: Patients with sickle cell trait or disease must be evaluated carefully due to the reported risk of severe sickle cell crises.
• Pregnancy and Lactation: Use during pregnancy is conditional, as potential fetal harm is possible based on animal data. It is not established if the drug passes into breast milk.

Established Eligibility

• Age Groups: The medicine is established for use in adults and pediatric patients for approved indications. No specific dose adjustment is required for older adults.
• Organ Function: Severe renal or hepatic impairment does not require dose adjustment, as its regulatory profile is similar to that in individuals with normal function.

Interactions with other medicines and products

Nivestym (filgrastim) is a biologic medicine whose official interaction profile is defined primarily by mandatory timing rules and one specific pharmacodynamic caution, as documented by governmental regulatory authorities. The official labeling does not document interactions involving classic pharmacokinetic mechanisms, such as the Cytochrome P450 (CYP) enzyme system, nor are interactions with food, alcohol, or herbal products specified.

---

Timing-Based Administration Restrictions

Official regulatory documents mandate strict timing requirements when Nivestym is used alongside cytotoxic therapies:

• Cytotoxic Chemotherapy: Nivestym must not be administered during the period 24 hours prior to cytotoxic chemotherapy.
• Post-Treatment Administration: Nivestym must be administered a minimum of 24 hours following the completion of cytotoxic chemotherapy or 24 hours after bone marrow infusion.

---

Pharmacodynamic and Substance Interactions

Regulatory agencies advise caution for the co-administration of certain substances due to the risk of additive effects on white blood cell counts.

• Lithium: Agents such as lithium, which may potentiate the release of neutrophils, should be used with caution. This is due to the potential for additive pharmacodynamic effects on neutrophil production.
• Contraindicated Combinations: No drugs are formally listed as contraindicated for co-administration due to a direct drug-drug interaction risk.

Nivestym (filgrastim-aafi) is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog. Its biological target is the G-CSF receptor (G-CSFR) expressed on the surface of hematopoietic progenitor cells and mature neutrophils within the bone marrow and peripheral blood. The drug acts as an agonist, binding to the receptor and inducing its dimerization.

This ligand-receptor binding initiates multiple intracellular signaling pathways, primarily the JAK/STAT, PI3K/AKT, and MAPK/ERK cascades. Activation of these pathways modulates gene transcription to regulate cellular processes. The collective intracellular consequences include enhanced survival, proliferation, and differentiation commitment of granulocyte progenitor cells, specifically those of the neutrophil lineage.

The downstream cascade results in an accelerated maturation of these precursors. System-level physiological modulation involves a significant increase in the production and subsequent release of mature, functional neutrophils from the bone marrow storage pool into the systemic circulation, leading to an elevated circulating neutrophil count.

Nivestym is administered by subcutaneous (SC) injection, a short intravenous (IV) infusion (15 to 30 minutes), or a continuous IV infusion. The subcutaneous route is preferred for most indications. Dosing is calculated based on the patient's body weight and specific condition.

Administration Details and Timing

Indication	Starting Dosage and Frequency	Administration Timing
Myelosuppressive Chemotherapy	5 mcg/kg/day	Administer at least 24 hours after cytotoxic chemotherapy. Do not administer within the 24 hours prior to chemotherapy.
Bone Marrow Transplantation (BMT)	10 mcg/kg/day (IV infusion)	Administer first dose at least 24 hours after chemotherapy and at least 24 hours after bone marrow infusion.
Severe Chronic Neutropenia (SCN)	Congenital: 6 mcg/kg SC twice daily. Idiopathic/Cyclic: 5 mcg/kg SC daily.	Long-term daily use is required, with dose adjustments based on Absolute Neutrophil Count (ANC).

Preparation and Procedural Rules

Before use, remove the vial or prefilled syringe from the refrigerator and allow it to reach room temperature for a minimum of 30 minutes. The solution must be visually inspected and should be clear and colorless; do not use if discoloration or particulates are present. The prefilled syringe should not be shaken. For IV administration, the product (vial only) must be diluted in 5% Dextrose Injection, USP, and should never be diluted with saline due to precipitation risk.

For subcutaneous self-injection, patients or caregivers are instructed to rotate injection sites among the outer area of the upper arms, abdomen, thighs, or upper outer areas of the buttock. Each vial or prefilled syringe is for single use only, and any unused portion must be discarded. If a dose is missed, patients should contact their healthcare provider for specific instructions.

Research Evidence / Overview of Studies for Nivestym

Evidence for Use in Preventing Neutropenia During Chemotherapy

Research for this medicine was conducted for patients receiving chemotherapy to explore the measured patterns of low white blood cell counts (neutropenia). The research includes randomized, placebo-controlled trials used in research exploring the original reference filgrastim product. These trials examined the measured recovery time of the absolute neutrophil count (ANC) and the measured incidence of Febrile Neutropenia (FN)—outcomes capturing phases of heightened symptom activity.

The Nivestym biosimilar was evaluated in comparative studies researching outcomes against the original product. These studies reported measurements designed to show non-inferiority in measured activity and outcomes related to systemic or functional imbalance across short-term cycles of chemotherapy. There is limited information for long-term outcomes based on the biosimilar’s own trials.

Evidence for Use in Acute Myeloid Leukemia (AML)

The research base for this medicine was evaluated in large, placebo-controlled trials with the reference product in patients with Acute Myeloid Leukemia (AML) following intensive chemotherapy. Research explored patterns in overall survival and complete remission rates; the findings did not indicate statistically significant differences in these long-term outcomes compared to the placebo groups.

Evidence for Use in Severe Chronic Neutropenia (SCN)

These research studies include long-term, non-randomized observational cohorts and patient registries that studied patients with conditions characterized by fluctuating or episodic manifestations like SCN. These studies explored the effects of long-term observation in patients over periods extending for many years. The long-term effects on bone marrow are tracked through surveillance and remain subjects of continued observation and reporting.

What is Still Uncertain About Nivestym Research

While comparative studies suggest functional equivalence to the reference product, the certainty remains low for outcomes beyond acute clinical changes, such as overall survival in AML patients. Long-term effects are not fully established for the biosimilar itself, particularly when applied in studies examining short-term or episodic symptom patterns after chemotherapy. Furthermore, comparative evidence is lacking outside of the limited, non-inferiority trials, and subgroup findings are uncertain for many specialized patient characteristics. The research provides context; study results reflect the specific conditions under which they were conducted.

Common questions about Nivestym (FAQ)

---

Q: Can I take Nivestym at the same time as my chemotherapy?

Official regulatory information indicates that Nivestym is not to be given simultaneously with chemotherapy. Specific timing rules apply: it is not to be administered in the 24 hours before cytotoxic chemotherapy. Administration is to occur at least 24 hours after your chemotherapy treatment is finished.

---

Q: Can Nivestym be diluted with normal saline?

Regulatory guidance specifies that if the medicine requires dilution for intravenous (IV) administration, it is not to be diluted with saline. It must only be diluted with 5% Dextrose Injection, USP. Saline is advised against because it carries a risk of precipitation, which means the drug could separate out of the solution.

---

Q: Can I take Nivestym if I am pregnant or breastfeeding?

The decision to use Nivestym during pregnancy is conditional; potential fetal harm is possible based on animal data. For breastfeeding, it is not established if the medicine passes into breast milk, and the effects on an infant are currently unknown.

---

Q: Can I take Nivestym with other medications that increase my white blood cell count?

Caution is advised in regulatory documents when taking Nivestym with other agents that may increase white blood cell counts, such as lithium. This is due to the potential for additive effects that could further increase neutrophil production. All concurrent medications should be reviewed by a healthcare professional.

---

Q: How should I dispose of the used syringes and vials?

For safe disposal, used prefilled syringes and needles are directed to be placed immediately in an FDA-cleared sharps disposal container. The medicine is for single use only, and any unused portion in vials or syringes is to be discarded. Used sharps are not to be disposed of in household trash.

---

Q: Is Nivestym a chemotherapy drug?

Nivestym is not classified as a chemotherapy drug. It is a Granulocyte Colony-Stimulating Factor (G-CSF) analogue. Its function is to act on the bone marrow to stimulate the production of neutrophils (a type of white blood cell), often used to help manage complications that can arise from chemotherapy.

---

Q: How long is the course of treatment with Nivestym?

The required duration of treatment varies significantly depending on the specific condition being treated. For patients receiving chemotherapy, treatment may last up to two weeks, while for conditions like Severe Chronic Neutropenia, long-term daily administration is required.

---

Q: What is the maximum daily dose for an adult?

Official prescribing information does not list a single fixed maximum dose for all adults. Dosing is calculated based on the patient's body weight and the specific condition being treated, such as chemotherapy or bone marrow transplantation.

---

Q: Does Nivestym cause weight loss or weight gain?

Weight changes are not listed among the most common side effects. However, some post-marketing reports for filgrastim products have noted weight loss as a possible side effect. Changes in weight should be discussed with a healthcare professional.

Nivestym requires specific cold storage and careful handling as mandated by regulatory documents to preserve its stability.

Storage Requirements

Nivestym must be stored in a refrigerator between 2 C to 8 C (36 F to 46 F) and must not be frozen. If accidentally frozen, it must be discarded if frozen more than once. The product must be protected from light by remaining in its original carton and must not be shaken. If removed from the refrigerator, it can be kept at room temperature (20 C to 25 C) for a maximum of 24 hours before being discarded. Keep the medicine out of the sight and reach of children.

Disposal Instructions

Nivestym is for single use only, and any unused portion must be discarded immediately. All used prefilled syringes and needles must be placed immediately in an FDA-cleared sharps disposal container and must not be thrown in household trash or flushed down the toilet.